Form 8-K - Current report:
SEC Accession No. 0001193125-25-030143
Filing Date
2025-02-20
Accepted
2025-02-20 08:05:11
Documents
13
Period of Report
2025-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d897858d8k.htm   iXBRL 8-K 25600
  Complete submission text file 0001193125-25-030143.txt   148148

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20250214.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20250214_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20250214_pre.xml EX-101.PRE 11259
15 EXTRACTED XBRL INSTANCE DOCUMENT d897858d8k_htm.xml XML 3643
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 25643341
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)